New Platform for Treatment of Breast Cancer Developed

New Platform for Treatment of Breast Cancer Developed
shutterstock_145412335 (1)In a new study entitled “Antiproliferation Activity of a Small Molecule Repressor of Liver Receptor Homolog 1” researchers discovered a new synthetic compound that inhibits the protein LRH-1, a key mediator of breast and pancreatic cancer progression. The study was published in the journal Molecular Pharmacology. Liver receptor homolog-1 (LRH-1) is a key protein required for the correct functioning of both intestine and pancreas. It is highly expressed in tissues originating from the endodermis, such as the lungs and intestines, and besides its key role in tissue normal physiology, LRH-1 also regulates pathways involved in cancer development. In breast cancer cell lines, LRH-1 rendered cancer cells more motile and invasive, in both cancer cells positive and negative for estrogen-receptor (ER). Thus, targeting LRH-1 has become a strategy for anti-cancer therapeutics in certain cancers. In this study, a team of researchers at The Scripps Research Institute, Florida, report the discovery and characterization of a new synthetic
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.